Zoe Quandt, MD
Assistant Professor
Diabetes Center
School of Medicine

Dr. Quandt is an endocrinologist at UCSF and the San Francisco VA with particular interest in endocrine autoimmune disease like type 1 diabetes and endocrine complications of cancer treatments, particularly immunotherapy. She does clinical and translational research trying to better understand who gets these complications and why. She is the clinical lead for adults eligible for teplizumab, an immunotherapy approved to delay the onset of type 1 diabetes.

Education & Training

Show all (5) Hide

• BA Biology Brown University
• Residency Internal Medicine Stanford Hospital and Clinics
• MS Health and Medical Sciences UC Berkeley
• Fellowship Endocrinology and Diabetes UCSF
• MD Medical School UCSF

Publications (41)

Top publication keywords:
Antineoplastic Agents, ImmunologicalProgrammed Cell Death 1 ReceptorKidney NeoplasmsAutoimmune DiseasesNeoplasmsDiabetes Mellitus, Type 1Lung NeoplasmsHypoglycemic AgentsCTLA-4 AntigenMammary Glands, HumanMelanomaCarcinoma, Renal CellEndocrine System DiseasesB7-H1 AntigenAutoimmunity

• Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
  Nature communications 2024 Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM, Princess Margaret Lung Group, Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M…
• Abstract 3460: Predicting cessation of immune checkpoint inhibitor therapy due to severe adverse events with an integrated autoimmune disease polygenic risk score.
  Cancer Research 2024 Pooja Middha, Rohit Thummalapalli, Zoe Quandt, Princess Margaret Lung Group, Matthew A. Gubens, Christine M. Lovly, Geoffrey Liu, Melinda C. Aldrich, Adam J. Schoenfeld, Elad Ziv
• Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.
  NPJ breast cancer 2024 Gallagher EJ, Moore H, Lacouture ME, Dent SF, Farooki A, Goncalves MD, Isaacs C, Johnston A, Juric D, Quandt Z, Spring L, Berman B, Decker M, Hortobagyi GN, Kaffenberger BH, Kwong BY, Pluard T, Rao R,…
• Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
  Frontiers in endocrinology 2023 Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG
• Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors.
  The oncologist 2023 Silverstein J, Wright F, Wang M, Young A, Kim D, De Dios K, Brondfield S, Quandt Z

Show all (36 more) Hide

• Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
  medRxiv : the preprint server for health sciences 2023 Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM, Princess Margaret Lung Group, Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M…
• Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
  Frontiers in endocrinology 2023 Gomes-Lima CJ, Zhou W, Quandt Z
• Signal detection in real-world data and confirmation in clinical trials: Diabetes as a case study for a conversation worth having.
  Cancer 2023 Sharon E, Othus M, Quandt ZE
• Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.
  Journal of Clinical Oncology 2023 Saya Jacob, Zoe Quandt, Michelle E. Melisko, Melanie Majure, Amy Jo Chien, Anne Hudson Blaes, Diane Heditsian, Laura Esserman, Hope S. Rugo
• The cognitive load of inpatient consults involving immune-related adverse events.
  Journal of Clinical Oncology 2023 Sam Brondfield, Jordyn Silverstein, Kimberly de Dios, Zoe Quandt
• Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis.
  Journal of the Endocrine Society 2023 Quandt Z, Kim S, Villanueva-Meyer J, Coupe C, Young A, Kang JH, Yazdany J, Schmajuk G, Rush S, Ziv E, Perdigoto AL, Herold K, Lechner MG, Su MA, Tyrrell JB, Bluestone J, Anderson M, Masharani U
• Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression.
  Nature biotechnology 2023 Gravina A, Tediashvili G, Rajalingam R, Quandt Z, Deisenroth C, Schrepfer S, Deuse T
• Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy.
  Diabetes 2023 Mandel-Brehm C, Vazquez SE, Liverman C, Cheng M, Quandt Z, Kung AF, Parent A, Miao B, Disse E, Cugnet-Anceau C, Dalle S, Orlova E, Frolova E, Alba D, Michels A, Oftedal BE, Lionakis MS, Husebye ES, …
• Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq.
  eLife 2022 Vazquez SE, Mann SA, Bodansky A, Kung AF, Quandt Z, Ferré EMN, Landegren N, Eriksson D, Bastard P, Zhang SY, Liu J, Mitchell A, Proekt I, Yu D, Mandel-Brehm C, Wang CY, Miao B, Sowa G, Zorn K, Chan AY…
• Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).
  Journal of Clinical Oncology 2022 Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Faye Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, …
• Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.
  JCI insight 2022 Perdigoto AL, Deng S, Du KC, Kuchroo M, Burkhardt DB, Tong A, Israel G, Robert ME, Weisberg SP, Kirkiles-Smith N, Stamatouli AM, Kluger HM, Quandt Z, Young A, Yang ML, Mamula MJ, Pober JS, Anderson MS…
• 189-OR: Immune-Profiling of Pancreatic Tissue Affected by Immune Checkpoint Inhibitor–Induced Diabetes (CPI-D).
  Diabetes 2022 ZOE QUANDT, ARABELLA YOUNG, GRAHAM BARLOW, SHEN DONG, JENNIFER SMITH, IRINA KUSMARTSEVA, TODD M. BRUSKO, STEWART COOPER, MARK S. ANDERSON
• Evaluating survival following severe immune-related adverse events requiring hospitalization.
  Journal of Clinical Oncology 2022 Francis Wright, Daniel Myung Kim, Jordyn Silverstein, Michelle Wang, Kimberly de Dios, Arabella Young, Zoe E. Quandt, Sam Brondfield
• Immune checkpoint inhibitor–induced diabetes mellitus across NCI trials.
  Journal of Clinical Oncology 2022 Zoe E. Quandt, Vanessa Hill, Joe E. Dib, Jason Burian, Sapir Tessler, Abdul Rafeh Naqash, Mark S Anderson, Megan Othus, Elad Sharon
• Autoantibody discovery across monogenic, acquired, and COVID19-associated autoimmunity with scalable PhIP-Seq.
  bioRxiv : the preprint server for biology 2022 Vazquez SE, Mann SA, Bodansky A, Kung AF, Quandt Z, Ferré EMN, Landegren N, Eriksson D, Bastard P, Zhang SY, Liu J, Mitchell A, Mandel-Brehm C, Miao B, Sowa G, Zorn K, Chan AY, Shimizu C, Tremoulet A,…
• Patient-Centered Diabetes Care of Cancer Patients.
  Current diabetes reports 2021 Kotwal A, Cheung YM, Cromwell G, Drincic A, Leblebjian H, Quandt Z, Rushakoff RJ, McDonnell ME
• Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Luo J, Martucci VL, Quandt Z, Groha S, Murray MH, Lovly CM, Rizvi H, Egger JV, Plodkowski AJ, Abu-Akeel M, Schulze I, Merghoub T, Cardenas E, Huntsman S, Li M, Hu D, Gubens MA, Gusev A, Aldrich MC, …
• Case 20: Partial ß-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes.
  2021 Zoe Quandt, Paras Mehta, Katy Tsai, Victoria Hsiao, Robert Rushakoff
• Case 21: Checkpoint Inhibitor–Induced Diabetes.
  2021 Paras Mehta, Zoe Quandt, Robert Rushakoff
• Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors.
  Annual review of medicine 2020 Quandt Z, Young A, Perdigoto AL, Herold KC, Anderson MS
• Breaking β Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus.
  Journal of the Endocrine Society 2020 Quandt Z, Coupe C, Anderson M, Uihlein A, Young A
• Identification of novel, clinically correlated autoantigens in the monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq.
  eLife 2020 Vazquez SE, Ferré EM, Scheel DW, Sunshine S, Miao B, Mandel-Brehm C, Quandt Z, Chan AY, Cheng M, German M, Lionakis M, DeRisi JL, Anderson MS
• SAT-418 Finding the Needles in the Haystack: Harnessing the Electronic Health Record to Find Thyroid Immune Related Adverse Events.
  Journal of the Endocrine Society 2020 Zoe Quandt, Laura Trupin, Michael Evans, Gabriela Schmajuk, Mark Stuart Anderson, Jeff A Bluestone, Yazdany Jinoos
• SAT-667 Partial Beta-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes Mellitus.
  Journal of the Endocrine Society 2020 Zoe Quandt, Katy K Tsai, Victoria C Hsiao
• SUN-298 Spectrum of Imaging in Immune Checkpoint Inhibitor Induced Hypophysitis.
  Journal of the Endocrine Society 2020 Zoe Quandt, Stephanie Kim, Javier Villanueva-Meyer, Catherine Coupe, J Blake Tyrrell, Jeffery A Bluestone, Mark Stuart Anderson, Umesh Masharani
• Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.
  Clinical and experimental immunology 2020 Quandt Z, Young A, Anderson M
• Chapter 19 Thyroid Disorders During Pregnancy, Postpartum, and Lactation.
  Maternal-Fetal and Neonatal Endocrinology 2020 Zoe E. Quandt, Kirsten E. Salmeen, Ingrid J. Block-Kurbisch
• Elastase 3B mutation links to familial pancreatitis with diabetes and pancreatic adenocarcinoma.
  The Journal of clinical investigation 2019 Moore PC, Cortez JT, Chamberlain CE, Alba D, Berger AC, Quandt Z, Chan A, Cheng MH, Bautista JL, Peng J, German MS, Anderson MS, Oakes SA
• Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome.
  The lancet. Diabetes & endocrinology 2019 Perdigoto AL, Quandt Z, Anderson M, Herold KC
• The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.
  Cancer immunology research 2018 Young A, Quandt Z, Bluestone JA
• Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.
  Diabetes 2018 Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC
• Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.
  Journal of Clinical Oncology 2018 Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Sarah E Umetsu, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe …
• Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC).
  Journal of Clinical Oncology 2018 Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Alexander Cheung, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, …
• Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer.
  Molecular and clinical oncology 2017 Serling-Boyd N, Quandt Z, Allaudeen N
• The association of alcohol consumption with mammographic density in a multiethnic urban population.
  BMC cancer 2015 Quandt Z, Flom JD, Tehranifar P, Reynolds D, Terry MB, McDonald JA
• Association of age, stature, and education with ocular dimensions in an older white population.
  Archives of ophthalmology (Chicago, Ill. : 1960) 2009 Lee KE, Klein BE, Klein R, Quandt Z, Wong TY